Paper published in “Biochimica et Biophysica Acta” describes how MUC1-C is involved in driving a program that integrates the induction of EMT with activation of stem cell traits, epigenetic reprogramming and immune evasion in human carcinomas.
The MUC1-C-integrated program provides support for the importance of this oncoprotein in cancer progression and emphasizes a critical need for developing agents against this widely overexpressed target in human malignancies.
Studies published in “Oncogene” have identified a highly important role for MUC1-C in activating a program of immune evasion in human cancer cells
The findings show that MUC1-C drives PD-L1 expression and represses effectors, such as interferon-gamma among others, of innate and adaptive immunity. Targeting MUC1-C in human cancers thus represents a novel therapeutic strategy for reversing tumor-associated suppression of immune recognition and destruction.